The use of caffeine as a metabolic probe for human drug metabolizing enzymes
- 31 March 1996
- journal article
- research article
- Published by Elsevier BV in General Pharmacology: The Vascular System
- Vol. 27 (2), 245-249
- https://doi.org/10.1016/0306-3623(95)02014-4
Abstract
No abstract availableKeywords
This publication has 24 references indexed in Scilit:
- Simple and reliable CYP1A2 phenotyping by the paraxanthine/caffeine ratio in plasma and in salivaPharmacogenetics, 1994
- Determination of CYP1A2 and NAT2 phenotypes in human populations by analysis of caffeine urinary metabolitesPharmacogenetics, 1992
- Biotransformation of caffeine, paraxanthine, theobromine and theophylline by cDNA-expressed human CYP1A2 and CYP2E1Pharmacogenetics, 1992
- Biotransformation of caffeine and theophylline in mammalian cell lines genetically engineered for expression of single cytochrome P450 isoformsBiochemical Pharmacology, 1992
- 1‐Methylxanthine derived from theophylline as an in vivo biochemical probe of allopurinol effect.British Journal of Clinical Pharmacology, 1991
- Relationship between plasma oxipurinol concentrations and xanthine oxidase activity in volunteers dosed with allopurinol.British Journal of Clinical Pharmacology, 1988
- Allopurinol dosage selection: relationships between dose and plasma oxipurinol and urate concentrations and urinary urate excretion.British Journal of Clinical Pharmacology, 1988
- Effect of allopurinol on caffeine disposition in man.British Journal of Clinical Pharmacology, 1986
- Secondary metabolism of theophylline biotransformation products in man‐ route of formation of 1‐methyluric acid.British Journal of Clinical Pharmacology, 1983
- Effects of allopurinol on theophylline metabolism and clearanceClinical Pharmacology & Therapeutics, 1979